MedTrace Logo

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

NCT06928753 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1800

Last updated 2025-07-29

No results posted yet for this study

Summary

Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.

Conditions

  • Chikungunya Virus Infection

Interventions

BIOLOGICAL

IXCHIQ

Group of vaccinated arm will be with the IXCHIQ vaccine

Sponsors & Collaborators

  • ANRS, Emerging Infectious Diseases

    collaborator OTHER_GOV

  • Région La Réunion

    collaborator UNKNOWN

  • ARS La Réunion

    collaborator UNKNOWN

  • Direction Générale de l'offre de Soins (DGOS)

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire de la Réunion

    lead OTHER

Principal Investigators

  • Patrick GERARDIN, MD · CHU La Réunion

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-18
Primary Completion
2026-04-30
Completion
2026-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06928753 on ClinicalTrials.gov